Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes

被引:64
作者
Lugari, R
Dell'Anna, C
Ugolotti, D
Dei Cas, A
Barilli, AL
Zandomeneghi, R
Marani, B
Lotti, M
Orlandini, A
Gnudi, A
机构
[1] Univ Parma, Dept Endocrinol, I-43100 Parma, Italy
[2] Univ Modena, Dept Internal Med, I-41100 Modena, Italy
关键词
GLP-1; entero-insular axis; diabetes;
D O I
10.1055/s-2007-978665
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Exogenous glucagon-like peptide 1(GLP-1) bioactivity is preserved in type 2 diabetic patients, resulting the peptide administration in a near-normalization of plasma glucose mainly through its insulinotropic effect. GLP-1 also reduces meal-related insulin requirement in type 1 diabetic patients, suggesting an impairment of the entero-insular axis in both diabetic conditions. To investigate this metabolic dysfunction, we evaluated endogenous GLP-1 concentrations, both at fasting and in response to nutrient ingestion, in 16 type 1 diabetic patients (age = 40.5 +/- 14 yr, HbA1C = 7.8 +/- 1.5%), 14 type 2 diabetics (age = 56.5 +/- 13 yr, HbA1C = 8.1 +/- 1.8%), and 10 matched controls. In postabsorptive state, a mixed breakfast (230 KCal) was administered to all subjects and blood samples were collected for plasma glucose, insulin, C-peptide and GLP-1 determination during the following 3 hours. In normal subjects, the test meal induced a significant increase of GLP-1 (30', 60': p < 0.01), returning the peptide values towards basal concentrations. In type 2 diabetic patients, fasting plasma GLP-1 was similar to controls (102.1 +/- 1.9 vs. 97.3 +/- 4.01 pg/ml), but nutrient ingestion failed to increase plasma peptide levels, which even decreased during the test (p < 0.01). Similarly, no increase in postprandial GLP-1 occurred in type 1 diabetics, in spite of maintained basal peptide secretion (106.5 +/- 1.5 pg/ml). With respect to controls, the test meal induced in both diabetic groups a significant increase in plasma glucagon levels at 60' (p < 0.01). In conclusion, either in condition of insulin resistance or insulin deficiency chronic hyperglycemia, which is a common feature of both metabolic disorders, could induce a progressive desensitization of intestinal L-cells with consequent peptide failure response to specific stimulation.
引用
收藏
页码:424 / 428
页数:5
相关论文
共 29 条
[1]
ROLE OF HYPERGLUCAGONEMIA IN MAINTENANCE OF INCREASED RATES OF HEPATIC GLUCOSE OUTPUT IN TYPE-II DIABETICS [J].
BARON, AD ;
SCHAEFFER, L ;
SHRAGG, P ;
KOLTERMAN, OG .
DIABETES, 1987, 36 (03) :274-283
[2]
Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients [J].
Creutzfeldt, WOC ;
Orskov, C ;
Kleine, N ;
Holst, JJ ;
Willms, B ;
Nauck, MA .
DIABETES CARE, 1996, 19 (06) :580-586
[3]
BOTH SUBCUTANEOUSLY AND INTRAVENOUSLY ADMINISTERED GLUCAGON-LIKE PEPTIDE-I ARE RAPIDLY DEGRADED FROM THE NH2-TERMINUS IN TYPE-II DIABETIC-PATIENTS AND IN HEALTHY-SUBJECTS [J].
DEACON, CF ;
NAUCK, MA ;
TOFTNIELSEN, M ;
PRIDAL, L ;
WILLMS, B ;
HOLST, JJ .
DIABETES, 1995, 44 (09) :1126-1131
[4]
GLUCAGON-LIKE PEPTIDE-I REDUCES POSTPRANDIAL GLYCEMIC EXCURSIONS IN IDDM [J].
DUPRE, J ;
BEHME, MT ;
HRAMIAK, IM ;
MCFARLANE, P ;
WILLIAMSON, MP ;
ZABEL, P ;
MCDONALD, TJ .
DIABETES, 1995, 44 (06) :626-630
[5]
Subcutaneous glucagon-like peptide I combined with insulin normalizes postcibal glycemic excursions in IDDM [J].
Dupre, J ;
Behme, MT ;
Hramiak, IM ;
McDonald, TJ .
DIABETES CARE, 1997, 20 (03) :381-384
[6]
Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans - Studies with the antagonist exendin 9-39 [J].
Edwards, CMB ;
Todd, JF ;
Mahmoudi, M ;
Wang, ZL ;
Wang, RM ;
Ghatei, MA ;
Bloom, SR .
DIABETES, 1999, 48 (01) :86-93
[7]
THE ENTEROINSULAR AXIS REVISITED - A NOVEL ROLE FOR AN INCRETIN [J].
ENSINCK, JW ;
DALESSIO, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (20) :1352-1353
[8]
INSULINOTROPIC GLUCAGON-LIKE PEPTIDE-I(7-37)/(7-36)AMIDE - A NEW INCRETIN HORMONE [J].
FEHMANN, HC ;
HABENER, JF .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 1992, 3 (05) :158-163
[9]
ANTIDIABETOGENIC EFFECT OF GLUCAGON-LIKE PEPTIDE-1 (7-36)AMIDE IN NORMAL SUBJECTS AND PATIENTS WITH DIABETES-MELLITUS [J].
GUTNIAK, M ;
ORSKOV, C ;
HOLST, JJ ;
AHREN, B ;
EFENDIC, S .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (20) :1316-1322
[10]
KREYMANN B, 1987, LANCET, V2, P1300